retatrutide triple agonist weight loss trial Eli Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial loss. Read about the work via the link in the comments 🎙️ NEW EPISODE: Retatrutide—The Triple

Deflating News Informally referred to as Ozempic face, individuals who achieve substantial weight loss often experience a loss of elasticity and facial volume that had normally been provided by facial fat

The peptide appears to exert pleiotropic biological effects involving modulation of angiogenic signaling, inflammatory mediators, cytoprotective pathways, and cellular migration/proliferation processes

Are BPC-157 and BPC-159 intended for human consumption

Research has shown that sustained use of these drugs could help patients lose close to 10% of their weightand in the process fight comorbidities like diabetes and heart disease

Chronic conditions like arthritis or recurring tendinopathies often benefit from ongoing management rather than time-limited treatment